GeneBioTech Cash And Equivalents vs. Shares Owned By Institutions
| 086060 Stock | KRW 3,410 5.00 0.15% |
For GeneBioTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of GeneBioTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well GeneBioTech Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between GeneBioTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of GeneBioTech Co over time as well as its relative position and ranking within its peers.
GeneBioTech |
GeneBioTech Shares Owned By Institutions vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining GeneBioTech's current stock value. Our valuation model uses many indicators to compare GeneBioTech value to that of its competitors to determine the firm's financial worth. GeneBioTech Co is number one stock in cash and equivalents category among its peers. It also is number one stock in shares owned by institutions category among its peers . The ratio of Cash And Equivalents to Shares Owned By Institutions for GeneBioTech Co is about 13,268,231,268 . Comparative valuation analysis is a catch-all model that can be used if you cannot value GeneBioTech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GeneBioTech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.GeneBioTech Shares Owned By Institutions vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
GeneBioTech |
| = | 7.43 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
GeneBioTech |
| = | 0.56 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
GeneBioTech Shares Owned By Institutions Comparison
GeneBioTech is currently under evaluation in shares owned by institutions category among its peers.
GeneBioTech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in GeneBioTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, GeneBioTech will eventually generate negative long term returns. The profitability progress is the general direction of GeneBioTech's change in net profit over the period of time. It can combine multiple indicators of GeneBioTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. The company was founded in 1984 and is headquartered in Gongju, South Korea. GeneBioTech is traded on Korean Securities Dealers Automated Quotations in South Korea.
GeneBioTech Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on GeneBioTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of GeneBioTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the GeneBioTech's important profitability drivers and their relationship over time.
Use GeneBioTech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneBioTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneBioTech will appreciate offsetting losses from the drop in the long position's value.GeneBioTech Pair Trading
GeneBioTech Co Pair Trading Analysis
The ability to find closely correlated positions to GeneBioTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneBioTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneBioTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneBioTech Co to buy it.
The correlation of GeneBioTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneBioTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneBioTech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneBioTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your GeneBioTech position
In addition to having GeneBioTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronic Equipment Thematic Idea Now
Electronic Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electronic Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronic Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in GeneBioTech Stock
To fully project GeneBioTech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of GeneBioTech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include GeneBioTech's income statement, its balance sheet, and the statement of cash flows.